Full text is available at the source.
Role of glucagon-like peptide 1 receptor agonists in management of obesity
How drugs that activate GLP-1 receptors help manage obesity
AI simplified
Abstract
An estimated 69% of U.S. adults are overweight, with nearly 35% classified as obese.
- GLP-1 receptor agonists are effective for weight reduction in both patients with and without type 2 diabetes.
- These agents improve weight loss by enhancing feelings of fullness and slowing down the rate of stomach emptying.
- Liraglutide, marketed as Saxenda, is the only GLP-1 receptor agonist approved by the FDA specifically for long-term weight management.
- Clinical trials suggest that GLP-1 receptor agonists offer weight loss results comparable or superior to other antiobesity medications.
- The safety profile of GLP-1 receptor agonists is generally more favorable, with mild-to-moderate gastrointestinal symptoms being the most common side effects.
AI simplified